LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma

NCT00859222 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

51

Enrollment

OTHER

Sponsor class

Conditions

Malignant Glioma

Interventions

DRUG: LBH589
DRUG: bevacizumab

Sponsor

Patrick Y. Wen, MD

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]